Trial Profile

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 May 2025 Results presented in a Savara Pharmaceuticals media release
18 May 2025 According to a Savara Pharmaceuticals media release, new data from this trial presented at the poster presentations at the ATS International Conference 2025.
07 Apr 2025 According to a Savara Pharmaceuticals media release, data from the study will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13, 2025, in Tokyo, Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com